Alsuraifi, A, Kong Thoo Lin, P, Curtis, A, Lamprou, D and Hoskins, C (2018) A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines. Pharmaceuticals, 11 (4). ISSN 1424-8247

[thumbnail of pharmaceuticals-11-00091.pdf]
pharmaceuticals-11-00091.pdf - Published Version
Available under License Creative Commons Attribution.

Download (4MB) | Preview


Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity. The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 μg mL−1.

Item Type: Article
Additional Information: This is the final published version (version of record). It was first published via MDPI and is available via - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: nanomedicine, nanopharmaceutics, drug solubilisation, pancreatic cancer, bisnaphthalimide
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Depositing User: Symplectic
Date Deposited: 25 Sep 2018 19:58
Last Modified: 25 Sep 2018 20:01

Actions (login required)

View Item
View Item